市場調查報告書
商品編碼
1593760
酵素市場:按產品類型、按類型、按來源、按反應類型、按應用、按地區、機會、預測,2017-2031 年Enzymes Market Assessment, By Product Type, By Type, By Source, By Reaction Type, By Application, By Region, Opportunities and Forecast, 2017-2031F |
預計全球酵素市場規模將從 2023 年的 120.6 億美元成長到 2031 年的 200.3 億美元,2024-2031 年預測期間複合年增長率為 6.55%。該市場的成長得益於全球製藥和醫療保健行業的擴張、尖端技術的崛起以及環保技術的日益使用。市場主要參與者增加對擴大生產設施的投資預計將有助於擴大其市場佔有率,並為市場提供利潤豐厚的成長機會。 2024 年 7 月,以利用酵素的力量為食品加工和製造提供創新解決方案而聞名的天野酶公司 (Amano Enzyme Inc.) 慶祝擴大其在美國伊利諾伊州的製造足跡。施工預計將於 2025 年 4 月完成,預計將支持公司提供創新的新型酵素。
此外,加強新酵素開發的合作研究的增加也支持了市場擴張。 2024年8月,Twist Bioscience Corporation和bitBiome, Inc.宣佈推出轉氨酶篩選試劑盒。轉氨酶已成為合成製藥行業必需的手性胺的一種選擇,為傳統合成提供了綠色替代方案。該試劑盒具有獨特的轉氨酶,可供製藥公司和實驗室用來合成活性藥物成分。此類合作預計將加強為各產業提供創新解決方案。
此外,烘焙食品消費的增加增強了全球對酵素的需求。美國烘焙協會估計烘焙業對美國的經濟影響超過1,860億美元。酵素和酵母在烘焙食品的生產中發揮重要作用,澱粉酶在麵包製作過程中發揮重要作用,蛋白酶對麵筋的物理性質有重大影響,半纖維素酶則影響麵粉的水結合能力。導致織物軟化的能力。因此,烘焙食品消費的擴大預計將為全球酵素市場提供利潤豐厚的成長機會。
本報告調查了全球酵素市場,並提供了市場概述,以及我們提供的產品類型、類型、來源、反應類型、應用、地區和進入市場的公司概況的趨勢。
Global enzymes market is projected to witness a CAGR of 6.55% during the forecast period 2024-2031, growing from USD 12.06 billion in 2023 to USD 20.03 billion in 2031. The market's growth is supported by expanding the global pharmaceutical and healthcare sectors, emerging advanced technologies, and increasing utilization of eco-friendly technologies. The rising investments by the market's key players towards the expansion of their production facilities are expected to aid them in expanding their market share and provide lucrative growth opportunities for the market. In July 2024, Amano Enzyme Inc., known for providing innovative solutions for food processing and manufacturing with the help of enzymes, celebrated the expansion of its manufacturing site in Illinois, United States. The construction is expected to be completed by April 2025 and is anticipated to support the company in delivering innovative new enzymes.
Furthermore, rising collaborations to augment the development of novel enzymes are also supporting the market's expansion. In August 2024, Twist Bioscience Corporation and bitBiome, Inc. announced the launch of their Transaminase Enzyme Screening Kit. Transaminase has emerged as an option for synthesizing chiral amines, which is essential for the pharmaceutical industry and offers a green alternative to conventional synthesis. The kit features unique transaminases that pharma companies and laboratories can use to synthesize active pharmaceutical ingredients. Such collaborations are expected to bolster the availability of innovative solutions for different industries.
Additionally, the increasing consumption of baked goods bolstered the global demand for enzymes. As per the estimates of the American Bakers Association, the baking industry has an economic impact of over USD 186 billion in the United States. Enzymes and yeasts play a significant role in the production of baked goods, with amylases playing a crucial role in the bread-making process, proteases having large effects on physical gluten properties, and hemicellulases holding the capacity to destroy the water binding capacity of wheat flour, causing softening of dough. Thus, the growing consumption of baked goods is expected to provide lucrative growth opportunities to the global enzymes market.
Integration of AI Provides Growth Opportunities
Startups across the globe are receiving funding to advance enzyme design with the help of generative (artificial intelligence) AI. In August 2024, BIOMATTER INC. secured approximately USD 7 million (€6.5M) in funding for their innovative approach to designing enzymes from scratch, allowing them to go beyond the limitations of natural enzymes. They can also tailor enzymes for different sectors, reducing the development time from years to weeks.
Meanwhile, the development of AI models for producing sequences that support the production of functional enzymes with the required characteristics for different applications is also expected to influence the global enzymes market's expansion positively. In June 2024, Basecamp Research and Ferruz Laboratory at the Institute of Molecular Biology of Barcelona announced the release of ZymCTRL in partnership. The ChatGPT-like tool is used to generate new sequences from scratch with the help of an enzyme identification code that specifies the desired activity. ZymCTRL also offers cost-effective and rapid design capabilities for generating artificial enzymes and requires no seed sequence as opposed to other large language models.
Rising Collaborations Among Biotech Companies Support Market Expansion
The rising efforts of the leading biotech companies to bolster the production of next-generation enzymes are boosting the global enzymes market size. In April 2024, Ginkgo Bioworks and Prozomix Limited announced a new partnership to build out the production of next-gen enzyme plates for manufacturing active pharmaceutical ingredients. The partnership aims to leverage Prozomix's deep experience in manufacturing enzyme plates and existing enzyme libraries, as well as Ginkgo's industry-leading artificial intelligence/machine learning (AI/ML) models and enzyme services. This collaboration will also support the entry of Prozomix in Ginkgo's Technology Network, bring together a wide range of partners that span manufacturing, biologics, genetic medicines, and AI, and aim to integrate their capabilities for providing customers with successful research and development outcomes and end-to-end solutions. Ginkgo's customers will also have access to Prozomix's contract manufacturing services, such as enzyme samples. Such partnerships are expected to boost the production of next-generation enzymes and provide lucrative growth opportunities to the enzyme market.
Industrial Enzymes Account for Significant Market Share
The growth of the segment can be attributed to the rapid expansion of various industries and increasing investments in industrial enzymes. Industrial enzymes act as biocatalysts in several traditional chemical processes to enhance process efficiency and sustainability and find applications in sectors including textiles, feed, and detergents, among others. In August 2024, Lallemand Inc. invested in LIVZYM BIOTECHNOLOGY as part of its strategic collaboration in the industrial enzyme segment. LIVZYM is the first producer of industrial enzymes based in Turkey, allowing the company to serve customers across the Middle East and Africa, Europe, and Asia. The strategic investment from Lallemand is expected to provide LIVZYM with a significant opportunity to advance alternative protein technologies and sustainability. Additionally, the utilization of industrial enzymes by the detergents industry is also increasing, with amylases, lipases, and proteases being added to laundry detergents to make them more effective at lower temperatures and improve stain removal.
North America Holds the Major Market Share
The rapid expansion of healthcare, pharmaceutical, food and beverage, and agriculture and livestock sectors in the region augments the growth of the North America enzymes market. The strong presence of key players in the United States also provides lucrative growth opportunities for the market. In January 2023, BASF SE and Cargill announced expanded cooperation to add the United States to their existing feed enzymes distribution and development agreement. The collaboration aided the companies in increasing the accessibility to animal feed among the business owners while ensuring the availability of high-performance enzyme solutions that have been shown to improve sustainability, reduce nutrient waste, and improve feed efficiency.
Meanwhile, the market is expected to witness significant growth in the Asia-Pacific region over the forecast period. This growth can be attributed to the rapid expansion of the food and beverage industry, growing requirements for processed foods, and rising demand for pharmaceuticals. As per the estimates of the India Brand Equity Foundation (IBEF), the domestic pharmaceutical industry is expected to reach USD 57 billion by FY2025. This growth is expected to propel the requirement for enzymes in the region as they are used directly for therapeutic applications as a drug as well as tools in manufacturing active pharmaceutical ingredients.
Future Market Scenario (2024-2031F)
As per the global enzymes market analysis, the market is expected to witness significant growth in the coming years due to the rising requirement for enzymes to meet the growing demand from pharmaceutical, food and beverage, and healthcare sectors, among others, in various regions across the globe. According to the estimates of the IBEF, the total market size of the pharma industry in India is expected to reach USD 450 billion by 2047. Such expansions are expected to bolster the market's demand and support its expansion in the Asia-Pacific region. Rising income levels and rapid population expansion are expected to increase enzyme requirements in the coming years. According to estimates from the United Nations, the global population is expected to grow to 9.7 billion by 2050. The expansion of the population is also expected to propel the reliance on the agriculture industry to meet the growing food demand, thus augmenting the requirement for soil treatment and positively influencing the market's expansion. Soil enzymes aid in increasing the rate of reaction at which plant residues start decomposing and releasing the available nutrients.
Key Players Landscape and Outlook
The key players in the market are increasingly engaging in mergers and acquisitions and collaboration activities to focus on their growth and expand their product portfolio. In October 2024, Codexis, Inc. announced that they have entered into a non-exclusive commercial and manufacturing licensing agreement for multiple enzymes in their life science enzyme portfolio with Alphazyme, LLC. The agreement involves the licenses for HiRev Isothermal Polymerase, HiTemp Reverse Transcriptase, and HiFi DNA Polymerase, among other enzymes. The transaction will enable Codexis, Inc., to focus on its strategic priorities as well as its near-term commercial opportunities. The agreement also marks another transaction in the company's strategy to divest their non-core assets to focus on the growth of their Enzyme Catalyzed Oligonucleotide (ECO) Synthesis manufacturing platform and the pharmaceutical manufacturing business.
In December 2023, Kerry Group announced that they had agreed to acquire Novozymes A/S and Chr. Hansen A/S's lactase enzyme business for approximately USD 162 million (€150 million). The European Commission cleared Hansen A/S and Novozymes A/S upon full compliance with the commitments. With the acquisition of the lactase enzyme business, Kerry Group will have access to technology that aids them in creating reduced-sugar and lactose-free dairy products.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.